Pär-Ola Bendahl
Lund University
210 Papers
1.4K Citations
Pär-Ola Bendahl is an academic researcher from Lund University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 48, co-authored 185 publications. Previous affiliations of Pär-Ola Bendahl include Linköping University.
Chat about Author
Papers
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
Christine Lundgren,Pär-Ola Bendahl,Åke Borg,Anna Ehinger,Cecilia Hegardt,Christer Larsson,Niklas Loman,Martin Malmberg,Helena Olofsson,Lao H. Saal,Tobias Sjöblom,Henrik Lindman,Marie Klintman,Jari Häkkinen,Johan Vallon-Christersson,Mårten Fernö,Lisa Rydén,Maria Ekholm,Maria Ekholm +18 more
TL;DR: A post hoc analysis showed that a combination of HG and Ki67 could identify patients very likely to have Luminal A tumours according to MS, and a large subgroup of patients (51% of the cohort) having > 90% Luminal B tumours could be identified.
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
TL;DR: The classification according to the St Gallen molecular subtypes in primary tumours and matched lymph nodes metastases, implicates a shift to a more aggressive subtype in synchronous lymph node metastases compared to the primary breast tumour.
Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer
Adalsteinn Gunnlaugsson,Elisabeth Kjellén,Per Nilsson,Pär-Ola Bendahl,Julian Willner,Anders Johnsson +5 more
TL;DR: A strong dose-volume relationship between small bowel volume and radiation enteritis during 5-FU-OXA-based chemoradiotherapy is indicated, indicating the application of maneuvers to minimize small bowel irradiation, such as using a “belly board” or the use of IMRT technique aiming at keeping the small bowelVolume receiving more than 15 Gy under 150 cc.
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
Sara Alkner,M.B. Jensen,Birgitte Bruun Rasmussen,Pär-Ola Bendahl,Mårten Fernö,Lisa Rydén,Henning T. Mouridsen +6 more
TL;DR: Although tumor AIB1 expression does not seem to be useful for the choice of tamoxifen versus an aromatase inhibitor in postmenopausal endocrine-responsive breast cancer,AIB1 is an interesting target for new anti-cancer therapies and further investigations of this biomarker is warranted.
Artificial neural network models to predict nodal status in clinically node-negative breast cancer
TL;DR: In this retrospective study, ANN showed promising result as decision-supporting tools for estimating nodal disease if prospectively validated, patients least likely to have nodal metastasis could be spared SLNB using predictive models.